Screen Reader Mode Icon
You may be aware of current news that has mentioned biosimilar drugs in the treatment of people with inflammatory bowel disease. Biosimilar drugs (e.g. Inflectra or Renflexis) are highly similar to their innovator biologic drug (e.g. Remicade), but not exactly the same. A few years ago, there was not enough research to conclude that patients in remission being treated with an innovator biologic could safely and effectively switch to a biosimilar. Since then, evidence from international sources (potentially applicable to Canadian patients) has accumulated and provincial jurisdictions (and private payers) are beginning to reconsider such a switch.

Crohn’s and Colitis Canada is seeking your feedback on how any potential changes could impact you as input to our support programs and advocacy efforts.

Please complete the following short survey. It will only take 5 minutes of your time. If you wish to discuss this issue or if you have any questions about the survey, please contact: help@crohnsandcolitis.ca 

Question Title

* 1. I live in the following province or territory:

Question Title

* 2. I live in a major urban area.

Question Title

* 3. I am a:

Question Title

* 4. Patient age:

Question Title

* 5. Are you (or your loved one) currently being treated with a biologic or biosimilar (Humira®, Remicade®, Inflectra®, Renflexis®, Stelara®, Entyvio®, Simponi®). Or were you treated with a biologic or biosimilar in the past?

Question Title

* 6. I have heard that patients with Crohn’s or ulcerative colitis may be told to switch from their current treatment to a less costly treatment sometime in the future. (e.g. switch from Remicade to Inflectra or Renflexis).

Question Title

* 7. How do you feel about this?

Question Title

* 8. Should a switch from your current treatment to another be enforced by your provincial or private payer where you live, what supports would you need? (e.g. special counselling from gastroenterologist; meeting with GI nurse; other).

Question Title

* 9. Please share any additional comments you may have.

Question Title

* 10. Can Crohn's and Colitis Canada contact you to discuss your response?

Thank you for completing this survey. Your input is very valuable to us and will contribute to an updated Crohn’s and Colitis Canada position statement. If you have any questions or further comments, please contact help@crohnsandcolitis.ca
0 of 10 answered
 

T